Drug Trial Radar · NCT05662033
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.
Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Dec 5, 2022
Primary completion
Oct 29, 2024
Study completion Oct 29, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Dec 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety and tolerability of AZD6793 suspension following oral administration of Single Ascending Dose (SAD) \[Part 1\] and Multiple Ascending Dose (MAD) \[Part 2\] in healthy participants. Additionally, the study will include Part 3 (bioavailability and food effect cohort) to assess the relative oral bioavailability between test formulation and oral suspension (reference formulation) as well as the effect of a high fat high calorie (HFHC) meal on the PK of AZD6793 test formulation, in comparison to fasting conditions, after a single oral dose of AZD6793 in healthy participants. Part 4 of the study (Chronic Obstructive Pulmonary Disease \[COPD\] cohort) is intended to evaluate AZD6793 safety, tolerability, and PK profile for the first time in participants with moderate to severe COPD. Part 1 (SAD), Part 2 (MAD) and Part 3 (Bioavailability and food effect cohort) have been completed. Although it was planned that 5 cohorts would be included in Part 1, only 4 cohorts (32 participants) were included. Part 3 of the study was concluded with 13 healthy participants.
Conditions
- Inflammatory Diseases
Interventions
AZD6793Drug
AZD6793 will be administered orally
PlaceboDrug
Placebo will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (SAD): Number of participants with adverse eventsTime frame: From screening up to Follow up visit (Day 6±1)
- Part 2 (MAD): Number of participants with adverse eventsTime frame: From screening up to Follow up visit (Day 14±1)
- Part 1 (SAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)Time frame: From screening, Treatment Day 1 to Day 4 up to Follow up visit (Day 6±1)
- Part 2 (MAD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
- Part 1 (SAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)Time frame: From screening, Treatment Day -1 to Day 4 up to Follow up visit (Day 6±1)
- Part 2 (MAD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
- Part 1 (SAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)Time frame: Day 1 to Day 3
- Part 2 (MAD): Number of participants with abnormal findings in 12 Lead Digital electrocardiogram (dECG)Time frame: Day 1 to Day 3, Day 5, Day 8 to Day 10
- Part 1 (SAD): Number of participants with abnormal findings in TelemetryTime frame: Day -1 to Day 3
- Part 2 (MAD): Number of participants with abnormal findings in TelemetryTime frame: Day -1 to Day 2 and Day 8 to Day 10
- Part 1 (SAD): Number of participants with abnormal findings in Physical examinationsTime frame: From screening, Treatment Day -1 to 4 and follow up visit
- Part 2 (MAD): Number of participants with abnormal findings in Physical examinationsTime frame: From screening, Treatment Day -1 to 10 and follow up visit
- Part 1 (SAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)Time frame: From screening, Treatment Day -1, Day 2, Day 4 and Follow up visit (Day 6±1)
- Part 2 (MAD): Number of participants with abnormal findings in Laboratory assessments (haematology, serum clinical chemistry, and urinalysis)Time frame: From screening, Treatment Day -1 to Day 10 up to Follow up visit (Day 14±1)
- Part 3 (Bioavailability): Maximum observed plasma (peak) drug concentration [Cmax]Time frame: Day 1 to Day 3
- Part 3 (Bioavailability): Area under plasma concentration-time curve from zero to infinity [AUCinf]Time frame: Day 1 to Day 3
- Part 3 (Food effect): Cmax of AZD6793Time frame: Day 1 to Day 3
- Part 3 (Food effect): AUCinf of AZD6793Time frame: Day 1 to Day 3
- Part 4 (COPD): Number of participants with adverse eventsTime frame: From screening up to Follow up visit (Day 34±2)
- Part 4 (COPD): Number of participants with abnormal findings in vital signs (supine Blood Pressure (BP), pulse, respiratory rate, peripheral oxygen saturation (SpO2) and oral body temperature)Time frame: From screening up to Follow up visit (Day 34±2)
- Part 4 (COPD): Number of participants with abnormal findings in 12 Lead electrocardiogram (ECG)Time frame: From screening up to Follow up visit (Day 34±2)
- Part 4 (COPD): Number of participants with abnormal findings in Physical examinationsTime frame: From screening, Treatment Day -1, 1, 14, 28 and follow up visit (34±2)
- Part 4 (COPD): Number of participants with abnormal findings in Laboratory assessments (haematology, clinical chemistry, coagulation tests, and urinalysis)Time frame: From screening up to Follow up visit (Day 34±2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Harrow, United Kingdom
Research Site
Wythenshawe, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.